Skip to main content

Table 3 Comparison of distribution of clinical factors between glioma patients with high and low ATG4C mRNA expression

From: Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux

Clinical characteristic

NO. of patients

p value

ATG4C low expression

ATG4C high expression

NO. of cases

487

488

 

Age (years)

  ≥ 55

297 (60.99%)

249 (51.02%)

0.002

  < 55

190 (39.01%)

239 (48.98%)

Gender

 Male

279 (57.29%)

294 (60.25%)

0.348

 Female

208 (42.71%)

194 (39.75%)

WHO grade

 II

121 (24.85%)

77 (15.78%)

0.000

 III

120 (24.64%)

96 (19.67%)

 IV

246 (50.51%)

315 (64.55%)

IDH status

 Wild

185 (37.99%)

130 (26.64%)

0.000

 Mutant

242 (49.69%)

298 (61.07%)

 Undefined

60 (12.32%)

60 (12.30%)

MGMT status

 Unmethylated

110 (22.59%)

224 (45.90%)

0.000

 Methylated

290 (59.55%)

170 (34.84%)

 Undefined

87 (17.86%)

94 (19.26%)